title: Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome.
abstract: OBJECTIVE
  The prognosis of advanced cutaneous T-cell lymphoma (CTCL), including Sézary syndrome and mycosis fungoides (MF), is poor. So far, no curative option apart from allogeneic stem cell transplantation is available. Large cell transformation often hallmarks cases with a more aggressive clinical course, and large tumor cells may express CD30. Recently, brentuximab vedotin, a conjugate of an anti-CD30 antibody and monomethylauristatin E, which inhibits the polymerization of microtubuli, has produced promising results in phase 2 trials in CD30+ Hodgkin lymphoma and anaplastic large cell lymphoma.
  
  
  METHODS
  We describe 4 patients with advanced CTCL, 3 with MF and 1 with Sézary syndrome, who were treated with brentuximab. All patients had received multiple previous systemic therapies. In 2 cases of MF, a remission enabling subsequent allogeneic stem cell transplantation was achieved.
  
  
  CONCLUSIONS
  Brentuximab is a well-tolerated, promising new treatment option for advanced CTCL that can be integrated in an allogeneic stem cell transplantation plan by selectively depleting malignant CD30+ cutaneous lymphoma cells.
authors.affiliation: Office of the Medical Directorate, University Hospital of Zürich, Zürich, Switzerland.
authors.forename: Tarun
authors.initials: T
authors.lastname: Mehra
authors.affiliation: Department of Pathology, University Hospital of Zürich, Zürich, Switzerland.
authors.forename: Kristian
authors.initials: K
authors.lastname: Ikenberg
authors.affiliation: Office of the Medical Directorate, University Hospital of Zürich, Zürich, Switzerland.
authors.forename: Rudolf Maria
authors.initials: RM
authors.lastname: Moos
authors.affiliation: Department of Hematology, Kantonsspital Münsterlingen, Münsterlingen, Switzerland.
authors.forename: Rudolf
authors.initials: R
authors.lastname: Benz
authors.affiliation: Division of Hematology, University Hospital of Zürich, Zürich, Switzerland.
authors.forename: Gayathri
authors.initials: G
authors.lastname: Nair
authors.affiliation: Division of Hematology, University Hospital of Zürich, Zürich, Switzerland.
authors.forename: Urs
authors.initials: U
authors.lastname: Schanz
authors.affiliation: Department of Pathology, University Hospital of Zürich, Zürich, Switzerland.
authors.forename: Eugenia
authors.initials: E
authors.lastname: Haralambieva
authors.affiliation: Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland.
authors.forename: Wolfram
authors.initials: W
authors.lastname: Hoetzenecker
authors.affiliation: Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland.
authors.forename: Reinhard
authors.initials: R
authors.lastname: Dummer
authors.affiliation: Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland.
authors.forename: Lars Einar
authors.initials: LE
authors.lastname: French
authors.affiliation: Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland.
authors.forename: Emmanuella
authors.initials: E
authors.lastname: Guenova
authors.affiliation: Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland.
authors.forename: Antonio
authors.initials: A
authors.lastname: Cozzio
mesh_terms: D000328:Adult; D000368:Aged; D000079963:Brentuximab Vedotin; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D018796:Immunoconjugates / Q000009:adverse effects / Q000627:therapeutic use*; D017730:Ki-1 Antigen / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000188:drug therapy* / Q000473:pathology; D011379:Prognosis; D012751:Sezary Syndrome / Q000188:drug therapy* / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D033581:Stem Cell Transplantation / Q000379:methods; D014184:Transplantation, Homologous / Q000379:methods
chemical_list: D018796:Immunoconjugates; D017730:Ki-1 Antigen; D000079963:Brentuximab Vedotin